Josh Wingrove,

Josh Wingrove is a reporter who covers health and political topics with a focus on US Agency actions and policies. He has reported on the reclassification of marijuana as a less dangerous drug, the push to reduce border crossings, and the potential impact of US steel deals on American workers. His work often highlights the implications of policy decisions for both domestic and international audiences.

Biography:  https://www.bloomberg.com/authors/ASLqWCO-Zh4/josh-wingrove

100%

The overall score is a weighted number that takes into account conflict of interest, bias, deception and other practices that undermines the credibility of the source. It is calculated as:
Analysis.OverallConflictOfInterestScore * 0.3F + Analysis.OverallBiasScore * 0.3F + Analysis.DeceptivenessScore * 0.3F + Analysis.ReadabilityScore * 0.1F

A score that takes into consideration the content for flow, interruptions with ads, and overt search engine optimization techniques that makes the content hard to understand

The Daily's Verdict

This author is known for its high journalistic standards. The author strives to maintain neutrality and transparency in its reporting, and avoids conflicts of interest. The author has a reputation for accuracy and rarely gets contradicted on major discrepancies in its reporting.

Bias

100%

Examples:

  • Josh Wingrove reports on health and political topics with a focus on US Agency actions and policies.

Conflicts of Interest

100%

Examples:

No current examples available.

Contradictions

100%

Examples:

No current examples available.

Deceptions

100%

Examples:

No current examples available.

Recent Articles

DEA and DOJ Consider Reclassifying Marijuana: Implications for Medical Research and the Cannabis Industry

DEA and DOJ Consider Reclassifying Marijuana: Implications for Medical Research and the Cannabis Industry

Broke On: Tuesday, 30 April 2024 The DEA and DOJ propose reclassifying marijuana from a Schedule I to a Schedule III drug, recognizing its medical benefits and easing research. If approved, marijuana would join drugs like ketamine in this category. The process involves DOJ recommendation, OMB review, DEA notice, public comment period, and Congressional Review Act action. Potential benefits include industry growth and new treatments; however, state-federal conflicts persist.